Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: In children and adults with XLH, burosumab treatment significantly increased renal tubular phosphate reabsorption and normalized serum phosphorus concentrations. Prolonged treatment with burosumab showed a favorable safety profile, improved healing of rickets in children, and fractures and pseudofractures in adults. FGF23 excess in CKD is independently associated with left ventricular hypertrophy and cardiovascular mortality. Research strategies to lower FGF23 in animal models of CKD are rapidly advancing and a question that remains to be answered is whether FGF23 blockade will offer a new targeted intervention for disordered mineral metabolism in CKD. SUMMARY: Findings from recently concluded clinical trials in adults and children with XLH provide evidence for improved skeletal health with burosumab therapy with normalization of phosphate and vitamin D metabolism. Targeted anti-FGF23 antibody treatment of XLH has emerged as a novel therapeutic strategy to treat an inherited disorder of FGF23 excess.
|
Authors | Shanthi Balani, Farzana Perwad |
Journal | Current opinion in nephrology and hypertension
(Curr Opin Nephrol Hypertens)
Vol. 29
Issue 5
Pg. 531-536
(09 2020)
ISSN: 1473-6543 [Electronic] England |
PMID | 32701599
(Publication Type: Journal Article, Review)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- FGF23 protein, human
- Phosphates
- Vitamin D
- Fibroblast Growth Factors
- Fibroblast Growth Factor-23
- burosumab
|
Topics |
- Animals
- Antibodies, Monoclonal, Humanized
(therapeutic use)
- Familial Hypophosphatemic Rickets
(drug therapy, metabolism)
- Fibroblast Growth Factor-23
- Fibroblast Growth Factors
(antagonists & inhibitors)
- Humans
- Phosphates
(metabolism)
- Renal Insufficiency, Chronic
(metabolism)
- Vitamin D
(metabolism)
|